Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
Author: Karnon, J.
Shafie, A.
Orji, N.
Usman, S.
Citation: Cost Effectiveness and Resource Allocation, 2016; 14(1):11-1-11-10
Publisher: BioMed Central
Issue Date: 2016
ISSN: 1478-7547
Statement of
Jonathan Karnon, Ainul Shakirah Shafie, Nneka Orji and Sofoora Kawsar Usman
Abstract: Zoledronic acid and denosumab were funded by the Australian government for the management of osteoporosis at an equivalent price to alendronate. The price of alendronate has declined by around 65 %, but the price of the other two therapies has remained stable. Using data published since the listing, this paper reports current estimates of the value of denosumab compared to alendronate from an Australian health system perspective.A cohort-based state transition model was developed that predicted changes in bone mineral density (BMD), and calibrated fracture probabilities as a function of BMD, age and previous fracture to estimate differences in costs and QALYs gained over a 10-year time horizon.The base-case incremental cost per QALY gained for denosumab versus alendronate was $246,749. There is a near zero probability that denosumab is cost-effective at a threshold value of $100,000 per QALY gained. If the price of denosumab was reduced by 50 %, the incremental cost per QALY gained falls to $50,068.Current Australian legislation precludes price reviews when comparator therapies come off patent. The presented analysis illustrates a review process, incorporating clinical data collected since the original submission to inform a price at which denosumab would provide value for money.
Keywords: Pharmaceutical pricing; Patent; Generic; Osteoporosis; Cost-effectiveness; Calibration
Rights: © 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( publicdomain/zero/1.0/)applies to the data made available in this article, unless otherwise stated.
RMID: 0030057354
DOI: 10.1186/s12962-016-0060-5
Appears in Collections:Public Health publications

Files in This Item:
File Description SizeFormat 
hdl_108495.pdfPublished Version1.04 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.